[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-neoplasms":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638305","neoadjuvant-radiotherapy-and-surgery-for-high-risk-localized-ewing-sarcoma-100638305",false,"NCT07620431","Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma","An Observational Study on the Safety and Efficacy of Neoadjuvant Concurrent Chemoradiotherapy Sequential Surgery for High-Risk Localized Ewing Sarcoma","Inclusion Criteria:\n\n1. The subject or their legal representative signs the written informed consent prior to enrollment.\n2. Age \\\u003C= 55 years old.\n3. Histologically confirmed Ewing sarcoma, with FET family (including EWSR1 or FUS) gene rearrangement confirmed by FISH or NGS. Clear FET-non ETS fusion cases are excluded.\n4. Deemed difficult to achieve a satisfactory surgical margin by 2 or more senior musculoskeletal oncologists.\n5. ECOG Performance Status: 0-1.\n6. Expected life expectancy \\>= 3 months.\n7. Women of childbearing potential must have a negative pregnancy test within 1 week prior to enrollment and agree to use contraception; male subjects must agree to use contraception or have undergone surgical sterilization during the study.\n\nExclusion Criteria:\n\n1. No opportunity for surgical resection after neoadjuvant chemotherapy.\n2. Extensive metastasis with no indication for local surgical resection.\n3. Uncontrolled concurrent medical conditions.\n4. Prior radiotherapy to the surgical site during front-line treatment.\n5. History of other malignant tumors within the past 5 years.\n6. Inability to cooperate with preoperative neoadjuvant radiotherapy (e.g., due to psychiatric factors).\n7. Any condition that, in the investigator's judgment, might harm the patient or prevent compliance with study requirements.","ALL","12 Months",{"count":19,"type":20},55,"ESTIMATED","OBSERVATIONAL","This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery and postoperative chemotherapy in patients with high-risk, resectable localized Ewing sarcoma.",[24,25],"Ewing Sarcoma","Bone Neoplasms",[27,28,29,30,31],"Neoadjuvant Radiotherapy","Preoperative Radiotherapy","Observational Study","Local Control Rate","Wound Healing","NOT_YET_RECRUITING","2026-05-27",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":20},"2026-06-01",{"date":40,"type":20},"2027-12-01",{"name":42,"class":43},"Peking University People's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100261087","an-electronic-health-record-ehr-based-comprehensive-bone-and-soft-tissue-tumor-registry-100261087","NCT02677961","An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry","Inclusion Criteria:\n\n* Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.)\n* Patient, or his\u002Fher designated power of attorney, must be able to understand and approve of the consent to participate.\n\nExclusion Criteria:\n\n* Prisoners are excluded from participation in the Registry.","18 Years",{"count":53,"type":20},1500,"5 Years","Translational studies in cancer research can be impeded by the lack of high-quality clinical data that can be correlated with research questions. This is particularly true in the case of rare diseases, such as bone and soft tissue tumors. It is therefore the purpose of this study to create a prospective EHR-based clinical registry for individuals with bone and soft-tissue tumors.",[57,25],"Neoplasms, Connective and Soft Tissue",[59,60],"sarcoma","registry","RECRUITING","2026-02-09",{"date":64,"type":36},"2026-02-11",{"date":66,"type":36},"2015-07-01",{"date":68,"type":20},"2027-12-31",{"name":70,"class":43},"Ohio State University Comprehensive Cancer Center",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100541852","radiotherapy-treatments-for-neoplasms-of-the-limbs-100541852","NCT06335251","Radiotherapy Treatments for Neoplasms of the Limbs","Inclusion Criteria:\n\n1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for:\n\n   Primary bone tumors, Primary soft tissue tumors, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system and skin, Secondary metastases from various origins localized in that district.\n2. Signed informed consent\n\nExclusion Criteria:\n\n1\\. Radiotherapy in districts other than limbs.",{"count":78,"type":20},3000,"In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included",[25,81],"Bone Metastases","2025-08-22",{"date":84,"type":36},"2025-08-28",{"date":86,"type":36},"2018-02-22",{"date":88,"type":20},"2025-12-31",{"name":90,"class":43},"European Institute of Oncology",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":44},"100591337","investigation-into-the-safety-and-efficacy-of-icg-labeled-fluorescence-imaging-technology-in-guiding-the-resection-of-bone-and-soft-tissue-tumors-100591337","NCT06979115","Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors","ICG-BST","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of bone and soft tissue tumors (according to the WHO Classification of Tumours of Soft Tissue and Bone, 4th Edition).\n2. Medically fit to undergo surgical treatment based on preoperative evaluation.\n3. Absence of cardiovascular, anesthesia-related, or other surgical contraindications.\n\nExclusion Criteria:\n\n1. Presence of severe or chronic kidney, liver, or pulmonary diseases.\n2. Autonomous thyroid nodules or allergy to iodine\u002Fshellfish.\n3. Deemed unable to tolerate surgery based on preoperative evaluation.",{"count":99,"type":20},40,"Investigate the application protocol, feasibility, and efficacy of indocyanine green (ICG)-assisted near-infrared (NIR) fluorescence-guided resection in bone and soft tissue tumors. Assess the incidence of adverse events and evaluate the safety of the protocol.",[25,102],"Soft Tissue Neoplasms",[104,105,106,107],"Soft tissue neoplasms","Bone neoplasms","Indocyanine green","Near-infrared","2025-05-12",{"date":110,"type":36},"2025-05-18",{"date":112,"type":20},"2025-05-25",{"date":114,"type":20},"2028-12-31",{"name":116,"class":43},"Guangdong Provincial People's Hospital"]